A PHASE II, OPEN-LABEL, MULTICENTER TRIAL OF CABAZITAXEL IN PATIENTS WITH RECURRENT OR METASTATIC HEAD AND NECK CANCER AFTER FAILURE OF CISPLATIN, CETUXIMAB AND TAXANES.
Phase of Trial: Phase II
Latest Information Update: 21 Jun 2016
At a glance
- Drugs Cabazitaxel (Primary)
- Indications Head and neck cancer
- Focus Therapeutic Use
- Acronyms ORL03
- Sponsors UNICANCER
- 11 Sep 2015 Primary endpoint (Disease control) has been met as results published at the 50th Annual Meeting of the American Society of Clinical Oncology.
- 21 Jun 2012 New trial record